Sagimet reports 52-week extension data for acne drug denifanstat; ends stock sales program
Sagimet reported 52-week results from the open-label extension of a Phase 3 acne trial of denifanstat, run by license partner Ascletis in China, with results presented at EADV 2026. The company also terminated its at-the-market stock sale prospectus supplement, so it will not sell shares under the Leerink Partners sales agreement unless a new prospectus or registration statement is filed.
Key points
- Extension trial reported 57% IGA success, 72% reduction in total lesions and 77% reduction in inflammatory lesions
- Denifanstat was generally well-tolerated, with no adverse event-related permanent discontinuations
- At-the-market prospectus supplement suspended and terminated effective September 30, 2026
- Patient screening for the US AURORA Phase 3 trial is expected to begin in October 2026
The filing
Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 30, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.